Efficacy of HAA regimen in the treatment of 64 patients with refractory/relapsed acute myeloid leukemia.
- VernacularTitle:HAA方案治疗复发难治性急性髓系白血病64例疗效观察
- Author:
Cuihua FAN
1
;
Wenjuan YU
;
Wenyuan MAI
;
Haitao MENG
;
Wenbin QIAN
;
Hongyan TONG
;
Jian HUANG
;
Liping MAO
;
Shanshan SUO
;
Jie JIN
Author Information
- Publication Type:Journal Article
- MeSH: Aclarubicin; analogs & derivatives; therapeutic use; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; therapeutic use; Harringtonines; therapeutic use; Humans; Leukemia, Myeloid, Acute; drug therapy; Recurrence; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Rate
- From: Chinese Journal of Hematology 2016;37(2):100-104
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the efficacy and safety of the HAA regimen (homoharringtonine,cytarabine and aclarubicin)as salvage chemotherapy in the treatment of refractory/relapsed acute myeloid leukemia (AML).
METHODSWe retrospectively analyzed 64 patients with refractory/relapsed AML who received the HAA regimen as salvage chemotherapy. The complete remission (CR)rate was analyzed. Kaplan-Meier method was used to estimate overall survival (OS) and relapse free survival (RFS), and the differences were compared by Log-rank test.
RESULTSThe overall CR rate was 70.1%, and 67.1% of the patients attained CR after the first induction course. The early death rate was 0. The median follow-up time was 61 (range:6-120) months. The estimated 3-year OS rate was 46.8% and the estimated 3-year RFS rate was 42.8%. The CR rates of patients with favorable/intermediate and unfavorable cytogenetics were 76.4% and 33.3%, respectively. The 3-year OS of favorable/intermediate and unfavorable group were 53.7% and 10.0%, respectively. The median survival time of unfavorable group was only 8 months. The side effects associated with the HAA regimen were tolerable, in which the most common toxicities were myelosuppression and infection.
CONCLUSIONHAA regimen is associated with a higher rate of CR and longer-term survival and its toxicity can be tolerated. The regimen is suitable for refractory/relapsed AML patients with favorable or intermediate risk .